Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Basic Policies for JP 18th Edition Now Up for Public Comments
August 23, 2016
- Japan to Target 95-100% SVR for Hep C, Compensated Cirrhosis in Revised 10-Year Strategy
August 23, 2016
- MHLW to Seek Funding to Promote and Support Healthcare Startups in FY2017 Budget Request
August 23, 2016
- MHLW to Seek Budgets to Develop Artificial Intelligence for Drug Discovery
August 22, 2016
- Japanese Pharmacopoeia 17th Edition Now Available in English
August 22, 2016
- G-CSF Preparations under PMDA Review for Anaphylaxis
August 22, 2016
- MHLW Set to Defend “High-Level Investment” Credits for Key R&D Tax Break System in FY2017 Reform
August 22, 2016
- Japan Approves 116 NMEs in FY2015, 37 on Priority Path: PMDA
August 19, 2016
- AMED Taking Steps toward “Aggressive Intellectual Property Management”: IP Department Head
August 18, 2016
- AMED Considers Giving Priority to Clinical Studies That Use Central IRBs: Official
August 16, 2016
- MHLW OKs First Generics for Tracleer, 6 Other APIs towards December Listing
August 16, 2016
- MHLW Study Group to Look at Measures to Popularize Biosimilars, Increase Efficiency in Development and Manufacturing
August 12, 2016
- Startup Promotion Guide to Support Major Companies as well: MHLW Official
August 10, 2016
- JMA, MHLW Say Possible Opdivo Re-Pricing Is Emergency Step, Won’t Make It Slippery Slope to Annual Revisions
August 9, 2016
- Key Govt Panel Sets Sights on Pricy Meds
August 9, 2016
- Japanese Society of Nephrology Wins AMED Funding for “Surrogate Endpoint” Guidelines
August 8, 2016
- MHLW Panel OKs Opdivo for RCC, ASKA’s Hepatic Encephalopathy Drug
August 8, 2016
- MHLW Unveils Draft Fast-Track Scheme for Drug-Resistant Infection Treatments
August 5, 2016
- MHLW Advisory Panel Backs Nesina-Metformin Combo
August 5, 2016
- 4 Bcr-Abl TKIs Ordered to Add Risk of HBV Reactivation in Labels: MHLW
August 5, 2016
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…